BioSpace News Archive

The California pharma is building up to its first-ever approval with promising late-stage data for its once-daily investigational acromegaly pill paltusotine, an alternative to the injectable standard of care.

The regulator Monday approved the companies’ supplemental Biologics License Applications for their respective mRNA shots formulated to more closely target currently circulating variants.

Following a Phase II review, Novartis has cut the development of a gene therapy candidate for geographic atrophy. In June, the company sold a dry eye disease drug to Bauch + Lomb for $1.75 billion.

The first-in-class antibody-drug conjugate—in combination with Merck’s Keytruda—has shown promising results in a Phase II study of patients with metastatic non-small cell lung cancer.

The collaboration, which includes an upfront payment of $120 million to Immatics, pairs Moderna’s mRNA technology with Immatics’ T-cell receptor platform for cancer treatment.

CymaBay Therapeutics, Inc. announced that it has commenced an underwritten public offering of an aggregate of $150 million of its common stock and pre-funded warrants.

Visgenx, Inc. announced that the Company presented a poster on its synthetic AAV platform at the Cell and Gene Therapy: Advancing Next Generation Therapies, West Coast Symposium on September 7th in Brisbane, California.

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announces initiation of a Phase 1 monotherapy expansion in the first-in-human clinical trial evaluating IDE161.

Eagle Pharmaceuticals, Inc. has been selected for a poster presentation at the conference co-sponsored by the American Society for Microbiology (“ASM”) and the European Society for Clinical Microbiology and Infectious Diseases (“ESCMID”).

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress syndrome (ARDS), today announced clinical data from the discontinued Phase 3 ARTEST clinical trial of enobosarm monotherapy for the 3rd line or greater in the metastatic setting of AR+ER+HER2- breast cancer.